LENZ News & Events

LENZ Therapeutics announced that it has submitted a Marketing Authorization Application, MAA, to the United Kingdom's Medicines and Healthcare products Regulatory Agency, MHRA, for the review and approval of VIZZ 1.44%, the first and only aceclidine-based eye drop for the treatment of presbyopia in adults. "As we advance in the early product launch in the United States, we continue to position VIZZ for broad international expansion which now includes a key regulatory advancement for the over 20 million adults in the United Kingdom affected by age-related blurry near vision. Positive early patient and ECP feedback on VIZZ has been resounding that our product provides a highly effective, once-daily alternative to reading glasses," said Eef Schimmelpennink, President and Chief Executive Officer of LENZ Therapeutics. "On the heels of our recent MAA submission to the European Medicines Agency, our submission to the MHRA is an important step to enable broad commercialization across Europe as we continue to build VIZZ into a global brand."

Reports Q4 revenue $1.59M, consensus $3.09M. "We are encouraged by the early performance of VIZZ. We undoubtedly have a product that works, with broad prescriber uptake and early signs of encouraging refill dynamics reinforcing its best-in-class profile," said Eef Schimmelpennink, president and CEO of Lenz Therapeutics. "We are clearly establishing a new category, with physicians building new habits of identifying appropriate patients and incorporating VIZZ into routine discussions. To accelerate this, we are leaning in by expanding our sales force, driving focused field execution and sharpening our physician messaging, as well as activating targeted consumer campaigns to establish VIZZ as a compelling alternative to reading glasses that is effective for the majority of presbyopes."